find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
365
Clinical Trials
Bone Marrow Transplant
N/A
Enrolling
nct/study# NCT04400591 / JCAR017-EAP-001
Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release.
Learn More
Bone Marrow Transplant
Phase I
Enrolling
nct/study# NCT05473910 / TSCAN-001
A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation
Learn More
Bone Marrow Transplant
N/A
Enrolling
nct/study# N/A / SIND-31754-LIFILEUCEL
Single Patient Non-Emergency Use IND of Lifileucel (Amtagvi) for Patient EAA
Learn More
NSCLC
Phase II
Enrolling
nct/study# 6568939 / M25-274
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Learn More
ES-SCLC
PIII
Closed to Enrollment
nct/study# 5468489 / HLX-10-005-SCL301-E
A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin- Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
Learn More
RRFL
1b/3
Closed to Enrollment
nct/study# 4224493 / EZH-302 / 245067
SYMPHONY-1: A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.